Navigation Links
University of Pittsburgh researchers launching trial of new osteoporosis drug

PITTSBURGH, Jan. 14 Endocrinologists at the University of Pittsburgh School of Medicine and UPMC are launching a human trial of a new drug that their research indicates holds great promise for building bones weakened by osteoporosis.

For the study, 105 participants will be randomly assigned to receive either teriparitide ( Forteo), a drug that already is FDA-approved for osteoporosis treatment, or an experimental agent called parathyroid hormone-related protein (PTHrP), explained principal investigator Mara J. Horwitz, M.D., an assistant Professor of Medicine in the Division of Endocrinology and Metabolism, Pitt School of Medicine, and a practicing metabolic bone specialist at UPMC.

"We are very eager to find out how this new drug compares to a therapy that is currently available," Dr. Horwitz said. "Our previous studies suggest that it may increase bone density more dramatically with fewer side effects, but this is the first head-to-head comparison."

On the cellular level, bone is constantly being broken down, a process known as resorption, and then rebuilt. In osteoporosis, this balancing act is off-kilter, leaving bones less dense and more vulnerable to fracture. Many drugs, such as alendronate (Fosamax), and raloxifene (Evista), work by decreasing bone resorption. They can improve bone density by two to 10 percent over several years to a decade and reduce fractures, but many patients' bone density already has been reduced by half when treatment begins.

Another kind of agent works on the other end of the bone metabolism see-saw: it promotes the creation of new bone. Teriparitide, a form of naturally occurring parathyroid hormone, currently is the only FDA-approved anabolic or bone-building agent in the United States. The experimental drug PTHrP, another protein made naturally by the body, also is an anabolic agent and appears to be unique in its ability to stimulate bone formation without simultaneously increasing bone breakdown. Both drugs are given as daily injections.

"When we studied PTHrP several years ago in small numbers of postmenopausal women with osteoporosis, we found that bone density increased by nearly 5 percent after only three months of treatment," said senior investigator Andrew F. Stewart, M.D., professor and chief of the Division of Endocrinology and Metabolism, Department of Medicine, Pitt School of Medicine. "And even at the highest doses, the side effects were negligible."

In findings published online last week in the Journal of Clinical Endocrinology and Metabolism, Drs. Horwitz and Stewart and their colleagues identified the maximum tolerable dose and therapeutic window of PTHrP. In this study, they were also able to show that PTHrP, at the tolerable doses, stimulated bone formation after only three weeks of treatment.


Contact: Anita Srikameswaran
University of Pittsburgh Schools of the Health Sciences

Related biology news :

1. New spider species discovered by University of Haifa scientists
2. University Hospitals Case Medical Center testing gene therapy for Alzheimers disease
3. Uniform method to interpret autism spectrum disorders is defined at Ben-Gurion University
4. Michigan State University study sheds light on microscopic flower petal ridges
5. Boston University reseachers develop faster, cheaper DNA sequencing method
6. University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium
7. Case Western Reserve University grants option to startup Thermalin Diabetes Inc.
8. Lehigh University professor receives Astellas Award for arsenic groundwater remediation efforts
9. University of Texas Southwestern Medical Center researcher wins Avanti Award in lipids
10. University of Washington professor garners Avanti Young Investigator Award
11. University of California, San Francisco, researcher receives ASBMB-Merck Award
Post Your Comments:
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Cepheid (Nasdaq: ... its participation at the Piper Jaffray Healthcare Conference in ... morning, the Company is reaffirming its outlook for the ... 2016, in addition to discussing longer term business model ... Chief Executive Officer.  "We continue to be the fastest ...
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Global Stem Cells Group announced the ... in the cities of Arica and Iquique in northern Chile. The facilities are part of ... the most advanced protocols and techniques in stem cell medicine to patients from around the ...
(Date:11/30/2015)... 2015  Culprits beware, a University at Albany ... Halámek, is taking crime scene fingerprint identification to ... -->   --> ... --> --> Halámek and his ... straightforward concept for identifying whether a culprit is ...
Breaking Biology Technology: